115 related articles for article (PubMed ID: 8655992)
1. Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS.
Piketty C; Bardin C; Gilquin J; Mahe V; Kazatchkine MD; Chast F
J Infect Dis; 1996 Jul; 174(1):188-90. PubMed ID: 8655992
[TBL] [Abstract][Full Text] [Related]
2. Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis.
Piketty C; Bardin C; Gilquin J; Gairard A; Kazatchkine MD; Chast F
Clin Microbiol Infect; 2000 Mar; 6(3):117-20. PubMed ID: 11168085
[TBL] [Abstract][Full Text] [Related]
3. Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review.
Zaknun D; Zangerle R; Kapelari K; Fischer H; Sailer M; McIntosh K
Pediatr Infect Dis J; 1997 Aug; 16(8):807-11. PubMed ID: 9271045
[No Abstract] [Full Text] [Related]
4. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group.
J Infect Dis; 1997 Jul; 176(1):50-8. PubMed ID: 9207349
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
6. New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Cunningham ET
West J Med; 1997 Feb; 166(2):138-9. PubMed ID: 9109331
[No Abstract] [Full Text] [Related]
7. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy.
Kuppermann BD; Quiceno JI; Flores-Aguilar M; Connor JD; Capparelli EV; Sherwood CH; Freeman WR
J Infect Dis; 1993 Dec; 168(6):1506-9. PubMed ID: 8245536
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus oral lesions: harbinger of retinitis in the absence of viraemia.
Cheung CY; Wong IY; Yan KW; Kwong YL
Ann Hematol; 2014 Sep; 93(9):1613-5. PubMed ID: 24420264
[No Abstract] [Full Text] [Related]
9. Absence of effect of glutamic acid hydrochloride on the bioavailability of oral ganciclovir in AIDS patients with cytomegalovirus disease.
Gambertoglio J; Kumar P; Dieterich D; Jacobson MA
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):394-6. PubMed ID: 9704949
[No Abstract] [Full Text] [Related]
10. Oral ganciclovir for cytomegalovirus infections.
Follansbee SE; Stempien MJ; Buhles WC
Adv Exp Med Biol; 1996; 394():93-103. PubMed ID: 8815713
[No Abstract] [Full Text] [Related]
11. Intravitreal ganciclovir for cytomegalovirus retinitis in patients with AIDS.
Montero MC; Pastor M; Buenestado C; Lluch A; Atienza M
Ann Pharmacother; 1996; 30(7-8):717-23. PubMed ID: 8826547
[TBL] [Abstract][Full Text] [Related]
12. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Jacobson MA; Drew WL; Feinberg J; O'Donnell JJ; Whitmore PV; Miner RD; Parenti D
J Infect Dis; 1991 Jun; 163(6):1348-51. PubMed ID: 1645385
[TBL] [Abstract][Full Text] [Related]
13. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates.
Smith IL; Shinkai M; Freeman WR; Spector SA
J Infect Dis; 1996 Jun; 173(6):1481-4. PubMed ID: 8648225
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
[TBL] [Abstract][Full Text] [Related]
15. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
Aweeka FT; Gambertoglio JG; Kramer F; van der Horst C; Polsky B; Jayewardene A; Lizak P; Emrick L; Tong W; Jacobson MA
Clin Pharmacol Ther; 1995 Apr; 57(4):403-12. PubMed ID: 7712668
[TBL] [Abstract][Full Text] [Related]
16. Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.
Yuen GJ; Drusano GL; Fletcher C; Capparelli E; Connor JD; Lalezari JP; Drew L; Follansbee S; Busch D; Jacobson M
Antimicrob Agents Chemother; 1995 Oct; 39(10):2350-2. PubMed ID: 8619596
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of cytomegalovirus retinitis in AIDS with an intraocular sustained-release ganciclovir implant].
Mochizuki M; Ikeda E; Yoshimura K; Hikita N; Nagata Y; Iwamoto A; Fujino Y; Eguchi S; Oka S; Kimura S
Nippon Ganka Gakkai Zasshi; 1998 Aug; 102(8):515-21. PubMed ID: 9754023
[TBL] [Abstract][Full Text] [Related]
18. Local therapy for cytomegalovirus retinitis.
Smith CL
Ann Pharmacother; 1998 Feb; 32(2):248-55. PubMed ID: 9496411
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151.
Jacobson MA; Kramer F; Bassiakos Y; Hooton T; Polsky B; Geheb H; O'Donnell JJ; Walker JD; Korvick JA; van der Horst C
J Infect Dis; 1994 Jul; 170(1):189-93. PubMed ID: 8014496
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
